Ataciguat
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Ataciguat
- Molecular weight
- 576.51
- Structure (SMILES)
- O=C(Nc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)s1
- ataciguat
- Ataciguat
- ataciguat (HMR1766)
- Ataciguat (HMR1766)
- ataciguat [INN]
- Ataciguat [WHO-DD]
- ataciguat inn
- ataciguat who dd
- CAS registry numbers
- 254877-67-3
- ChEMBL ID
- CHEMBL2107729
- InChIKey
- PQHLRGARXNPFCF-UHFFFAOYSA-N
- PubChem compound IDs
- 213037
- FDA ingredient codes (UNII)
- QP166M390Q
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- ataciguat
- Type
- Synthetic organic
- Drug name stem
- -ciguat
- Action
- Activation
- Action type
- ACTIVATION
- Target
- Guanylyl cyclase, α1β1
- Gene symbol
- GUCY1A1
- Protein identifier
- Q02108
- Action
- Activation
- Action type
- ACTIVATION
- Target
- Guanylyl cyclase, α1β1
- Gene symbol
- GUCY1B1
- Protein identifier
- Q02153
- Mechanism
- Soluble guanylate cyclase activator
- Action type
- ACTIVATOR
- Target
- Soluble guanylate cyclase
- Protein identifier
- O75343
- Mechanism
- Soluble guanylate cyclase activator
- Action type
- ACTIVATOR
- Target
- Soluble guanylate cyclase
- Protein identifier
- P33402
- Mechanism
- Soluble guanylate cyclase activator
- Action type
- ACTIVATOR
- Target
- Soluble guanylate cyclase
- Protein identifier
- Q02108
- Mechanism
- Soluble guanylate cyclase activator
- Action type
- ACTIVATOR
- Target
- Soluble guanylate cyclase
- Protein identifier
- Q02153
Open Targets mechanisms
- Mechanism
- Soluble guanylate cyclase activator
- Action type
- ACTIVATOR
- Target
- Soluble guanylate cyclase
- Condition
- Aortic Valve Stenosis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000266
- Subject identifier
- D001024
- Condition
- Pain
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003843
- Subject identifier
- D010146
- Condition
- Intermittent Claudication
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003876
- Subject identifier
- D007383
- Condition identifier
- EFO_0000266
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003876
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005762
- Highest recorded phase
- 2
- Condition identifier
- HP_0012531
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005386
- Highest recorded phase
- 2
- NCT00443287
- NCT00799656
- NCT02049203
- NCT02481258
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 2
- Polar surface area
- 121.88
- Calculated partition coefficient (ALogP)
- 4.13
- Calculated partition coefficient (XLogP)
- 4.2
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 7
- Heavy atoms
- 35
- Molecular formula
- C21H19Cl2N3O6S3
- Monoisotopic mass
- 574.9813042
- Natural product
- Yes
- Recorded assays
- 537
- Active assays
- 73
- Confirmatory
- Screening
- Summary
- Enzyme Activators
Related records
Trials (5)
- A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification
- Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
- Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease
- Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain
- Safety of Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis
In development for (2)
- Aortic valve stenosis Phase 2
- Intermittent vascular claudication Phase 2